Background. Health related quality of life (HRQoL) is one of the most important outcomes to measure effectiveness of an intervention, especially for islet transplantation in which benefits should outweigh risks of long-term immunosuppression. This study aimed to evaluate long-term effects of islet transplantation and to outline possible influential factors. Methods. Forty islet transplant recipients who completed 344 Health Status Questionnaires (HSQ 2.0) and 384 Diabetes Quality of Life Questionnaires (DQoL) between 2000 and 2007 were retrospectively reviewed. Assessments were analyzed in pretransplantation period, then every 3 months after the first infusion for 18 months and every 6 months thereafter. The mean follow-up posttransplantation was 40.8Ϯ21.9 months (9 -72 months). Results. Sustained improvement in DQoL-impact score was observed at all time-points posttransplantation. Similarly, worry and satisfaction scales were significantly better than pretransplant evaluation for most time-points. Four of eight HSQ 2.0 scales demonstrated a significant improvement at some time-points. Longitudinal analysis, after adjustments for potential confounding factors, showed significantly sustained improvement in impact scale up to 72 months. Longer diabetes duration, higher insulin dosage, and occurrence of adverse events had negative effects on HRQoL. Single islet infusion or islet after kidney transplant recipients showed the lowest values in HSQ 2.0. In contrast, subjects on exenatide therapy had significantly higher HSQ 2.0 scores. Conclusions. Islet transplantation is associated with long-term improvement in HRQoL. Exenatide usage had a positive effect whereas single islet infusion, islet after kidney transplantation, longer diabetes duration, higher insulin dosage, and adverse events had a negative impact on HRQoL scores.
I
slet transplantation is a therapeutic option for patients with type 1 diabetes mellitus with unstable metabolic control (1) (2) (3) . Despite the tendency for graft dysfunction overtime (1, 2, 4) , a significant improvement in diabetes quality of life (DQoL) has been shown in islet transplant recipients, up to 36 months postcompletion (5) . In addition, better Hypoglycemia Fear Survey scores after islet transplantation were observed in two cohorts (6, 7) . However, islet transplantation had none or minimal effects on generic health related quality of life (HRQoL) evaluated by the Health Status Questionnaires (HSQ 2.0), Health Utility Index Mark 2 (HUI2), and 36-Item Short Form Health Survey (SF-36) (5) (6) (7) . This could be explained by the use of generic HRQoL questionnaires, which provide more information about functional health status. Disease-specific HRQoL such as DQoL is known to be more sensitive in recording the negative effects arising from diabetic complications or changes after intervention (8 -10) . Insulin requirements, number of islet infusions, and glucose stability had an impact on HRQoL after islet transplantation (5, 6) ; however, a systematic evaluation of factors affecting the HRQoL are still lacking.
It is important that the benefit of islet transplantation should outweigh the risks of long-term use of immunosuppressive agents. HRQoL is another way to assess islet transplantation success. Until now, there has been no data evaluating long-term HRQoL after islet transplantation. Based on previous studies demonstrating short-term improvement in HRQoL after islet transplantation (5-7), we hypothesized whether this same outcome could also be achieved after long-term follow-up. The present study is an extension of the previous one (5) with a larger sample and longer follow-up, to explore long-term HRQoL and its influential factors in type 1 diabetes subjects after islet transplantation.
MATERIALS AND METHODS
Islet transplant recipients from 2000 to 2007 (4, (11) (12) (13) , who had HRQoL data available were retrospectively reviewed. A total of 40 of 44 recipients (19 males and 21 females) performed self-completed HRQoL questionnaires. All subjects were white and most of them were non-Hispanic except one. Seven subjects graduated from high school, 12 attended college, 14 finished associate or bachelor degree, and seven had postcollege graduate degree. These subjects underwent islet transplantation alone (IA) (nϭ26), islet after kidney transplant (IAK) (nϭ7), or islet with bone marrow transplant (IBM) (nϭ7). The pancreatic islet isolation, infusion, and immediate posttransplant management were performed as previously described (4) . Patients received one (nϭ15), two (nϭ18), three (nϭ6), or four (nϭ1) islet infusions. The decision of receiving single islet infusion was based on the protocol, patient request, poor compliance, side effects, or immunological sensitization. Maintenance immunosuppressive regimen was based on sirolimus (Rapamune, Wyeth Pharmaceuticals, Inc., Madison, NJ) and tacrolimus (Prograf, Astellas-Pharma US, Inc., Deerfield, IL). Eleven subjects switched from tacrolimus or sirolimus to mycofenolate mofetil or mycofenolate sodium because of adverse events (nϭ8), per protocol (nϭ2), or patient decision (nϭ1). Immunosuppressive drugs were discontinued in two subjects because of infection. Twenty-one subjects had received exenatide (Byetta, Amylin Inc., San Diego, CA) (mean 17Ϯ10 months, from 0.6 to 28.6 months) to improve graft function or islet engraftment (phase II study).
Both generic and disease-specific questionnaires were used as instruments to evaluate HRQoL. The generic health status was measured by the Health Status Questionnaire (HSQ 2.0), which reflects the health burden of chronic disease and the effect of treatments on general health status. It is adapted from SF-36 with the same questions and scoring algorithm except for bodily pain. HSQ 2.0 also includes the screening for dysthymia, major depression, index of health status change, and demographic items to assess factors associated with functioning and well-being. This instrument has been validated with good consistency and reliability (14) . HSQ 2.0 has eight scales: health perception, physical functioning, role limitationphysical health, role limitation-emotional problems, social functioning, mental health, bodily pain, and energy or fatigue. Disease-specific quality of life was assessed by DQoL which is designed to have three subscales to measure satisfaction of treatment, impact of therapy, worry about diabetes or social and vocational aspects. This questionnaire has been previously validated in type 1 diabetes (15). Both assessments have scores in each scale range 0 to 100 (from the worst to the best).
All subjects completed both questionnaires face to face at our clinic as a part of general psychological evaluation. The frequency of follow-up evaluation was designed to allow subjects the opportunities to report on their current experiences and perception based on timing of insulin independence, graft dysfunction and occurrence of adverse events (2) (3) (4) . The time-points analyzed were as follows: baseline (pretransplantation), every 3 months after the first infusion for 18 months and every 6 months thereafter. Pretransplant timepoints were also reviewed to investigate significant changes of HRQoL before transplant and this data was used as control. The questionnaires were grouped into 0 to 6, 6 to 12, and Ͼ12 months before islet transplantation. In addition, all subjects were asked the same open-ended questions to explain the most important benefit from islet transplantation, the impact of that benefit and whether they have any regrets participating in a clinical trial. Answers were recorded verbatim.
Baseline characteristics (e.g., age, sex, duration, and complications of diabetes), number of islet infusions, islet transplant protocol (IA, IAK, or IBM), glucose control (A1C), insulin dosage, exenatide administration, and adverse events pre-and posttransplantation were recorded. The adverse events were classified according to Common Terminology Criteria for Adverse Events, version 3.0 (National Cancer Institute; NCI) and categorized as NCI I (mild), II (moderate), III (severe), and IV (life-threatening). All protocol procedures were approved by the University of Miami health research ethics board and appropriate informed consent was obtained from each subject.
Statistical Analysis
Statistical analysis and graphics were performed using Excel for Windows, SAS 9.1 (SAS Institute Inc., Cary, NC) and SSPS 15.0 software. Data analyses were performed by using appropriate methods to the longitudinal nature. For each of the 11 HRQoL scale measurements under consideration, we performed repeated measure analysis by using linear mixed model regression. This method of analysis generalizes linear regression techniques to allow for repeated observations by taking into account the correlation that exists within observations on the same subject in estimating variances used for the various tests of significance. Using this approach, we are able to simultaneously estimate differences between baseline and each time-point postislet transplantation. We additionally used this approach to estimate bivariate associations between each HRQoL outcome and each potential explanatory factor considered in this research including age, diabetes duration, number of islet infusion, recent period (3 months) after each infusion, insulin dosage, A1C, protocol, exenatide usage, and adverse events. A more formal analysis of the data was then performed by incorporating these factors into the regression models for the effect of time, to provide adjustment for potential confounding. This analysis included data collected pretransplant and 14 time-points posttransplant up to 72 months. Missing data was handled with pairwise deletion analysis (16) . Baseline characteristics were expressed in meanϮSD. The model-based estimate concerning HRQoL scores were expressed in meanϮSEM. Differences were considered statistically significant at a P value Ͻ0.05.
RESULTS
Forty subjects answered 728 questionnaires that comprised 344 HSQ 2.0 and 384 DQOL. Mean follow-up pre and posttransplant were 23.2Ϯ22.6 months (1-106 months) and 40.8Ϯ21.9 months (9 -72 months), respectively. The mean age at the time of the first questionnaires obtained was 41Ϯ8.5 years old. Diabetes duration ranged from 5 to 45 years (mean 26.8Ϯ11.8). Chronic diabetes complications at baseline included retinopathy (nϭ27), nephropathy (nϭ12), neuropathy (nϭ16), hypertension (nϭ12), and stable coronary artery disease (nϭ1). At the time of data analysis, five subjects reached 72-month posttransplant follow-up. Data was available for only 29.9Ϯ19 months (9 -66 months) posttransplantation in 16 subjects because of loss of follow-up (nϭ1), side effects (nϭ4), graft loss (nϭ3), as per protocol (nϭ4) in IBM recipients (13) , and patient decision (nϭ4). Data completeness was achieved on 86.8% of the posttransplant time-points.
Seventy percent of the recipients reached insulin independence. At the end of the evaluation, seven patients (17.5%) were still insulin independent. A decrease in mean insulin requirements from 0.45Ϯ0.16 (0.13-0.8) to 0.12Ϯ0.16 (0 -0.76) IU/kg/day (PϽ0.001) and in A1C from 7.5Ϯ1.1 to 6.2Ϯ0.8% (PϽ0.001) were observed when all pretransplant were compared with posttransplant time-points.
Diabetes Quality of Life Questionnaires Postislet Transplantation
Impact scores were higher at all posttransplant timepoints in comparison with pretransplantation. Worry scale showed a significant improvement except in the first 3 months after first infusion. A significantly increase in satisfactory score was observed at most time-points, except at 3, 30 to 42, and 72 months (Table 1) .
Health Status Questionnaires Postislet Transplantation
A significant increase in HSQ 2.0 scales: health perception, physical functioning, social functioning, and bodily pain was observed at some time-points (Table 1 ). In contrast, there was a transient decrease of role limitation-physical health, role limitation-emotional problem, and mental health at various time points.
Pretransplant Questionnaire Evaluation
The analysis of HRQoL comparing 0 to 6 months (nϭ23) with Ͼ12 months (nϭ33) pretransplantation, showed significant increases in DQoL [satisfaction (80Ϯ2 vs. 69Ϯ3 at 0 to 6 and Ͼ12 months pretransplantation respectively, Pϭ0.016)] and HSQ [energy scales (79Ϯ4 vs. 70Ϯ3, Pϭ0.029)].
Factors Influencing Health Related Quality of Life
Diabetes duration, transplant protocol, number of islet infusions, insulin dosage, adverse events, and exenatide administration influenced various scales of HRQoL (Table 2) . IAK recipients had the lowest scores in many HSQ 2.0 scales in comparison with those from other protocols. Single islet infusion recipients, whose estimate mean insulin requirement was 0.14 IU/kg/day higher than recipients of two or more infusions (Pϭ0.003), had worse HSQ 2.0 scores (health perception, role limitation-emotion, social function, and energy scales) than multiple infusion recipients. To evaluate if a recent islet infusion had negative effect on quality of life, the scores available within 3 months after each infusion were compared with the other time-points and no significant difference in HRQoL, except for improvement of worry scale (Pϭ0.04), was observed.
Subjects on exenatide had higher HSQ 2.0: health perception and mental health scores and less NCI III-IV events (ORϭ0.4, 95%CI 0.17-0.93) than those without exenatide. Insulin requirement and A1C between these 2 groups was not different (PϾ0.05). From the interviewing aspect, they believed that exenatide would prolong islet graft survival and stabilize blood glucose control.
Higher A1C had a trend toward worse scores of most HRQoL scales without reaching statistical significance (changes of scores ranged from 0.99Ϯ0.7 to Ϫ3.1Ϯ4.1 for every 1% increase of A1C, PϾ0.05). Age and specific diabetic complications did not influence any HRQoL scales.
After adjusting for confounding factors, there was an improvement of HSQ 2.0: role-limitation emotion at 9 to 12 months, bodily pain at 72 months, and energy scale at 6 and 18 months posttransplantation (PϽ0.05). However, no significant decrease of the score was observed. Sustained improvement in DQoL was detected especially for worry and impact scales up to 60 and 72 months, respectively (Fig. 1) .
From the interview data, all subjects responded that having stable blood glucose control and not being afraid of having a hypoglycemic episode was the most important benefit after transplantation which led to the feeling of independence. No subject responded any regrets for transplantation. Moreover they had pleasure to be a part of the research.
DISCUSSION
HRQoL is one of the most important outcomes to measure effectiveness of an intervention. Improvement in HRQoL is associated with better diabetes self-management and lifestyle modifications (17) . In contrast, a decrease in HRQoL can have a negative impact on patient compliance (8) . This study combined generic and disease-specific instruments to include important aspects that could have an impact on HRQoL.
The present study, with a longer follow-up and a larger sample size than the previous publications (5, 7), demonstrated that the improvement of HRQoL was maintained up to 6 years after islet transplantation. DQoL in both unadjusted and adjusted analysis were clearly associated with significant improvement in all scales at most time-points. HSQ 2.0 failed to demonstrate the consistency of improvement after transplantation. This may be due to the subject attrition and also because this instrument focuses on more general aspects of health perception. A transient decrease in role limitation-emotional problem, role limitation-physical health, and mental health was detected but it was not sustained after adjustments for confounding factors.
Our results are different from the Diabetes Control and Complications Trial (DCCT), which did not find any improvement in both generic and disease-specific HRQoL after intensive insulin therapy when comparing with conventional treatment (18) . The stable metabolic control, insulin independence, or less insulin requirements after islet transplantation may have lead to a greater improvement in HRQoL than intensive insulin therapy. However, subjects selected for islet transplantation had more unstable diabetes than those in the HRQoL, Health related quality of life; DQoL, Diabetes Quality of Life; HSQ, Health Status Questionnaire; role-limit phys health, role-limitation physical health; role-limit emotion, role-limitation emotion;
DM, diabetes mellitus; IA, islet transplant alone; IAK, islet after kidney transplantation; IBM, islet with bone marrow transplantation; NCI, common terminology criteria for adverse events (National Cancer Institute); NS, nonsignificant.
DCCT trial, which could lead to more obvious change in HRQoL after intervention. Longer diabetes duration, higher insulin dosage and the occurrence of adverse events had significant negative effects on HRQoL. Our observations were similar to those from previous reports, in which worse HRQoL was associated with insulin usage (5, 9) . In contrast, higher A1C had a trend toward worse HRQoL but without statistical significance. This result was different from prior studies (19, 20) . Lack of significant changes might be due to stable glycemic control over time after islet transplantation.
Insulin independence after islet transplant is usually achieved after at least two islet infusions (2). Our study revealed that subjects who received only a single islet infusion had lower generic quality of life scores. Higher insulin requirements in this subgroup might be responsible for this observation. Also, after comparing different protocols, IAK recipients had the worst scores in most scales of HSQ 2.0, which might be explained by a more severe nature of the underlying disease.
Exenatide usage had positive effects on mental health and health perception scales of HSQ 2.0. The association of exenatide with a significantly lower rate of severe adverse events was unexpected. The latter might explain the benefits on quality of life after exenatide initiation. In addition, patients anticipated that exenatide would maintain or improve islet function and stabilize glucose control.
Most of posttransplant adverse events were procedure or medication-related and the higher incidence was during the first 3 months after infusion (4). We did not find any differences when comparing the HRQoL at 3 months postinfusion (regardless the number of infusions) with the other time-points, except for a better worry score at 3 months postinfusion period. This finding was similar to a previous study, which reported better emotion scores, evaluated by HUI2 after the first islet infusion (6) .
The limitation of this study was the lack of a control group. To overcome this issue, preislet transplantation data (nϭ68) were analyzed. Because subjects underwent HRQoL evaluation in more than one time-point before transplant, the comparison between pretransplant results were performed to evaluate the HRQoL changes before intervention. Even though, 2 of 11 HRQoL scales showed significant improvement before transplantation, the consistently better DQoL results maintained up to 6 years, indicate that improvement in HRQoL was most likely due to the islet transplantation effect. In addition, the verbal interview confirmed that the recipients were satisfied with the stability of their glucose control and absence of severe hypoglycemia. Subjects also reported a feeling of independence and being pleased with their participation in the clinical trial.
Another study limitation could have been the study withdrawals which could have positively affected the final outcome such as only patients benefited in the trial participated until the end of the study. In the future, randomized clinical trials aiming to compare HRQoL after islet transplantation with pancreatic transplantation or intensive insulin therapy in unstable type 1 diabetes as a control group should be conducted.
In conclusion, a consistent long-term improvement in HRQoL after islet transplantation reflecting by DQoL was observed. Exenatide usage had a positive effect on quality of life, whereas longer diabetes duration, islet after kidney transplantation, single islet infusion, adverse events occurrence, and higher insulin dosage had negative impact on health related quality of life. had significant improvement at 6 and 12-18 months after transplant. Impact scale (closed square) was significantly improved at 9 -48 and 60 -72 months. Worry scale (closed triangle) had significantly higher scores at 6 to 18 and 30 to 60 months (PϽ0.05).
